Liquidity shortfall and financing dependence
The company has recurring operating losses and may not fund its plan from existing cash.
- Scope
- Operating plan, development spend, commercialization
- Materiality
- high
Jaguar Health, Inc.
Jaguar Health, Inc. develops and commercializes plant-based prescription and non-prescription products for human and animal health, with a portfolio centered on crofelemer-based therapies and related botanical medicines. The company also uses licensing and partnership structures to extend its products and pipeline, including Mytesi, Canalevia-CA1, Gelclair, and early-stage botanical drug candidates through its Magdalena joint venture.
−382,2 %
99,2 %
−465,4 %
−1,5 %
0.50
0.29
| % | |
|---|---|
| Human prescription products | 55% Includes Mytesi, crofelemer-based follow-on indications, and licensed human therapies such as Gelclair. |
| Animal health products | 25% Includes Canalevia-CA1 and Neonorm products sold for companion animals and livestock. |
| License and royalty revenue | 15% Includes revenue from licensing arrangements such as the Gen territory agreement and other partner monetization. |
| Early-stage pipeline and collaborations | 5% Includes Magdalena and other botanical drug development efforts that are not yet commercial revenue drivers. |
Jaguar sells mainly to distributors, wholesalers, and specialty pharmacies, which then supply patients, veterinarians,...
- Distributors and wholesalersprimary
Buy Mytesi, Canalevia-CA1, and Neonorm products for onward sale into pharmacy and veterinary channels.
- Specialty pharmaciessecondary
Dispense Mytesi to patients under prescription and support access for niche human indications.
- Animal health channel partnerssecondary
Purchase animal products for resale to veterinarians, livestock operators, and end customers.
- Licensees and collaboration partnersprimary
Monetize territory rights or development assets and provide upfront or ongoing license revenue.
- Future pharmaceutical partnersemerging
Potential partners for crofelemer follow-on indications and Magdalena pipeline assets.
Jaguar is headquartered in the United States and generates most of its operating activity there, including product...
- •United States is the core operating and commercialization market
- •U.S. FDA approval and review timing are critical to pipeline value
- •International licensing expands reach without heavy foreign infrastructure
- •U.K.-based Venture Life is a source of licensed product rights
- •Global rights to crofelemer support future partnership optionality
Jaguar is focused on extending the commercial life of crofelemer while building new plant-based drug opportunities...
01
Advance crofelemer follow-on indicationsmedium-term
New indications could broaden the commercial opportunity beyond current products and create partnership value.
02
Monetize through partnerships and licensesshort-term
Upfront fees, territory licenses, and collaboration economics can fund operations without full internal commercialization costs.
03
Support existing product commercializationshort-term
Current product sales provide operating traction and validate the botanical drug platform.
04
Preserve liquidity and capital accessshort-term
The company has recurring losses and needs external funding to continue development and commercialization.
Jaguar remains a development-stage pharmaceutical company with recurring losses, limited cash, and dependence on...
FDA review and approval delays
Regulatory disruptions can slow submissions, meetings, inspections, and approvals.
- Scope
- Pipeline timing and product launches
- Materiality
- high
Minimum royalty payment obligations
Royalty interests require payments even if product sales are insufficient.
- Scope
- Cash flow and debt-like burden
- Materiality
- high
Clinical development failure
Pipeline assets depend on positive human trial and proof-of-concept results.
- Scope
- Crofelemer follow-on indications, Magdalena candidates
- Materiality
- high
Cost inflation and margin pressure
Higher raw material, labor, and distribution costs can compress gross margins.
- Scope
- Product revenue profitability
- Materiality
- medium
Revenue recognition for product and license revenue
Quarterly revenue mix can be volatile
Sales returns reserve
Can reduce reported net revenue
Fair value measurement of financial instruments
Can create non-cash earnings volatility
Debt extinguishment accounting
Affects operating loss comparability
Royalty obligations and minimum payments
Important for liquidity analysis and covenant-like pressure
: 28.4.2026